サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795344

肉腫治療の世界市場

Sarcoma Therapeutics

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
肉腫治療の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肉腫治療の世界市場は2030年までに36億米ドルに達する

2024年に23億米ドルと推定される肉腫治療の世界市場は、2024～2030年の分析期間においてCAGR 7.6%で成長し、2030年には36億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである軟部肉腫は、CAGR 9.0％を記録し、分析期間終了時には24億米ドルに達すると予測されます。骨肉腫セグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は6億3,090万米ドルと推定、中国はCAGR 12.1％で成長すると予測

米国の肉腫治療市場は、2024年には6億3,090万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.1%として、2030年までに7億7,060万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.3%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の肉腫治療市場- 主要動向と促進要因のまとめ

なぜ肉腫治療市場は高精度かつサブタイプに特化したアプローチへと進化しているのか？

間葉系組織から発生する多様な悪性腫瘍群である肉腫は、その稀少性、組織学的多様性、生物学的予測不可能性により、依然として最も複雑な腫瘍学的分類の一つです。骨肉腫、ユーイング肉腫から平滑筋肉腫、脂肪肉腫、滑膜肉腫まで70以上の組織型が同定されており、治療管理には高度に調整された集学的アプローチが要求されます。過去10年間で、腫瘍ゲノミクス、免疫腫瘍学、希少がん研究費の進歩により、一般的な化学療法レジメンから、サブタイプ特異的な精密標的療法へと徐々にではあるが大きな転換が見られました。

伝統的に、治療レジメンはアントラサイクリンベースの化学療法、特にドキソルビシンの単独療法またはイホスファミドとの併用療法に大きく依存してきました。しかし、いくつかの肉腫、特に転移性あるいは再発性の肉腫では、奏効率は依然として限定的です。このため腫瘍学の研究者たちは、特定の肉腫サブタイプに特有の遺伝子変異、転座、またはシグナル伝達経路を阻害する標的療法を開発するようになりました。例えば、マルチチロシンキナーゼ阻害剤であるパゾパニブは現在、非脂肪細胞性軟部肉腫に対して承認されており、イマチニブはKITまたはPDGFRA変異を有する消化管間質腫瘍（GIST）の治療に革命をもたらしました。これらの画期的な治療法は、肉腫治療を個別化されたバイオマーカー主導型治療の領域へと着実に変貌させつつあります。

どのような新しい治療法が、サブタイプ間の肉腫治療を再構築しているのか？

肉腫のパイプラインには、分子標的治療薬と免疫治療薬の両方の経路を通じて新規治療薬が参入しています。チロシンキナーゼ阻害剤（TKI）は、受容体や融合タンパク質の調節異常が知られている肉腫の治療の中心的存在であり続けています。例えば、レゴラフェニブとカボザンチニブはそれぞれGISTと骨肉腫に使用され、一次治療薬に反応しない患者に有望な活性を示しています。脂肪肉腫と平滑筋肉腫に承認されているトラベクテジンは、DNA結合と腫瘍微小環境の調節を通じて細胞毒性作用を発揮します。エリブリンやラロトレクチニブ（NTRK融合遺伝子陽性肉腫用）などの新しい薬剤は、特に化学療法抵抗性の変異型肉腫において治療の幅を広げています。

免疫療法は肉腫領域で勢いを増しているが、奏効はサブタイプによって異なります。PD-1/PD-L1を標的とするチェックポイント阻害剤は、未分化多形肉腫（UPS）や肺胞性軟部肉腫などの特定の肉腫で持続的な奏効を示しています。難治性患者を対象としたCTLA-4阻害剤、CAR-T細胞療法、腫瘍浸潤リンパ球（TIL）療法の臨床試験も行われています。免疫応答性肉腫に対する補助的戦略として、養子細胞療法やがんワクチンがまだ研究中ではあるが評価されています。さらに、現在進行中の血管新生阻害剤、HDAC阻害剤、DNA損傷応答モジュレーターの調査により、特に既存の化学療法との併用による治療の可能性が広がっています。

どのような患者集団と世界市場が先進肉腫治療の需要を牽引しているか？

肉腫は成人がん全体の1％未満であるが、小児や思春期の患者集団では不釣り合いに大きな負担となっています。ユーイング肉腫、横紋筋肉腫、骨肉腫などの小児肉腫は20歳未満に多く、有効性と長期的な安全性のバランスを考慮した治療が必要です。成人集団では、軟部肉腫が主流であり、しばしば積極的な全身療法を必要とする進行期病変を呈します。再発性あるいは転移性の肉腫患者では、治療開始後1年以内に標準治療を使い果たすことが多く、セカンドラインおよびサードラインの治療選択肢に対するニーズが特に高いです。

地域的には、北米と欧州が主要市場であり、強固な臨床試験インフラ、希少疾患研究資金、分子診断へのアクセスに支えられています。米国には肉腫紹介センターや患者支援団体が集中しており、医薬品開発の促進に積極的に取り組んでいます。欧州諸国は、肉腫に特化した登録や汎欧州臨床研究ネットワークの恩恵を受けています。アジア太平洋では、日本と韓国が肉腫に特化した医薬品パイプラインを拡充しており、インドと中国は医療アクセスの改善と腫瘍プロファイリング機能によって診断率が上昇しています。ラテンアメリカと中東は、特に化学療法をベースとした治療において、バイオシミラーと費用対効果の高い肉腫治療オプションの重点地域として浮上しています。

肉腫治療の市場成長を促進する主な要因は何か？

肉腫治療市場の成長は、疾患認知度の向上、分子診断薬の採用拡大、生物製剤へのアクセス拡大、希少がん研究の継続的な奨励など、いくつかの重要な要因によってもたらされます。生検方法の改善や免疫組織化学、FISH、次世代シーケンシング（NGS）へのアクセスにより、肉腫のサブタイプのより早期かつ正確な診断が可能になり、腫瘍医はより効果的に治療を調整できるようになっています。コンパニオン診断やバイオマーカー主導の治療プロトコルの導入により、製薬会社はサブタイプに特化した臨床試験や希少疾病用医薬品の開発に投資するようになっています。

さらに、FDAやEMAなどの規制機関が肉腫治療を希少疾病用医薬品に指定することで、開発企業は税額控除、市場独占権、迅速審査などのインセンティブを得ることができます。これらのプログラムは、軟部肉腫と骨肉腫の両方をターゲットとする実験的薬剤のパイプラインを促進しました。患者支援団体や世界の希少がんアライアンスは、知名度の向上、資金調達、研究への参加を促進することで、より迅速な治験の募集や規制当局による承認を促進しています。最後に、ヘルスケアの支払者は、肉腫管理における標的治療の費用対効果のバランスを認識し始めており、特に実際のデータが無増悪生存期間とQOLの改善を裏付けています。これらの相乗効果により、世界の肉腫治療市場は確固たる成長基盤を確立しつつあります。

セグメント

タイプ（軟部肉腫、骨肉腫）

調査対象企業の例

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Deciphera Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG（Genentech）
  • Fresenius Kabi AG
  • GSK plc
  • Ipsen S.A.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Sanofi S.A.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37969

Global Sarcoma Therapeutics Market to Reach US$3.6 Billion by 2030

The global market for Sarcoma Therapeutics estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Soft Tissue Sarcoma, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Osteosarcoma segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$630.9 Million While China is Forecast to Grow at 12.1% CAGR

The Sarcoma Therapeutics market in the U.S. is estimated at US$630.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$770.6 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Sarcoma Therapeutics Market - Key Trends & Drivers Summarized

Why Is the Sarcoma Therapeutics Landscape Evolving Toward Precision and Subtype-Specific Approaches?

Sarcoma, a diverse group of malignancies arising from mesenchymal tissues, remains one of the most complex oncologic categories due to its rarity, histological diversity, and biological unpredictability. With over 70 identified histological subtypes, ranging from osteosarcoma and Ewing sarcoma to leiomyosarcoma, liposarcoma, and synovial sarcoma, therapeutic management demands a highly tailored and multidisciplinary approach. The past decade has seen a gradual but significant shift from generalized chemotherapeutic regimens to subtype-specific and precision-targeted therapies, driven by advancements in tumor genomics, immuno-oncology, and rare cancer research funding.

Traditionally, treatment regimens have relied heavily on anthracycline-based chemotherapy, especially doxorubicin, either as monotherapy or in combination with ifosfamide. However, response rates remain limited in several sarcoma types, particularly those with metastatic or relapsed disease. This has prompted oncology researchers to develop targeted therapies that inhibit specific genetic mutations, translocations, or signaling pathways unique to certain sarcoma subtypes. For example, pazopanib, a multi-tyrosine kinase inhibitor, is now approved for non-adipocytic soft tissue sarcoma, while imatinib has revolutionized the treatment of gastrointestinal stromal tumors (GIST) harboring KIT or PDGFRA mutations. These breakthroughs are steadily transforming sarcoma therapeutics into a domain of individualized, biomarker-driven care.

What Emerging Therapies Are Reshaping Sarcoma Treatment Across Subtypes?

Novel therapeutics are entering the sarcoma pipeline through both targeted and immunotherapeutic pathways. Tyrosine kinase inhibitors (TKIs) continue to be central to managing sarcomas with known receptor or fusion protein dysregulation. For instance, regorafenib and cabozantinib are used in GIST and osteosarcoma respectively, showing promising activity in patients unresponsive to first-line agents. Trabectedin, approved for liposarcoma and leiomyosarcoma, exerts cytotoxic effects through DNA binding and modulation of the tumor microenvironment. Newer agents such as eribulin and larotrectinib (for NTRK fusion-positive sarcomas) are expanding the scope of treatment, particularly in chemoresistant variants.

Immunotherapy is gaining momentum in the sarcoma space, although responses vary across subtypes. Checkpoint inhibitors targeting PD-1/PD-L1 have shown durable responses in certain sarcomas like undifferentiated pleomorphic sarcoma (UPS) and alveolar soft part sarcoma. Trials are also investigating CTLA-4 inhibitors, CAR-T cell therapies, and tumor-infiltrating lymphocyte (TIL) therapies in refractory patients. Adoptive cell therapies and cancer vaccines, though still investigational, are being evaluated as adjunct strategies for immune-responsive sarcomas. Furthermore, ongoing research into angiogenesis inhibitors, HDAC inhibitors, and DNA damage response modulators is providing additional avenues for treatment, especially in combination with existing chemotherapy backbones.

Which Patient Populations and Global Markets Are Driving Demand for Advanced Sarcoma Therapies?

Although sarcomas constitute less than 1% of all adult cancers, they represent a disproportionately higher burden in pediatric and adolescent populations. Pediatric sarcomas such as Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma are more prevalent in individuals under 20 years of age, necessitating therapies that balance efficacy with long-term safety. In adult populations, soft tissue sarcomas dominate and often present with advanced-stage disease requiring aggressive systemic therapy. The need for second-line and third-line treatment options is particularly high among patients with recurrent or metastatic sarcomas, who often exhaust standard therapies within the first year of treatment.

Regionally, North America and Europe are the leading markets for sarcoma therapeutics, supported by robust clinical trial infrastructure, rare disease research funding, and access to molecular diagnostics. The U.S. sees a concentration of sarcoma referral centers and patient advocacy groups actively involved in accelerating drug development. European countries benefit from sarcoma-specific registries and pan-European clinical research networks. In Asia-Pacific, Japan and South Korea are expanding their sarcoma-focused drug pipelines, while India and China are witnessing a rise in diagnostic rates driven by improving healthcare access and tumor profiling capabilities. Latin America and the Middle East are emerging as focus regions for biosimilar and cost-effective sarcoma treatment options, especially for chemotherapy-based care.

What Are the Main Drivers Accelerating Market Growth for Sarcoma Therapeutics?

The growth in the sarcoma therapeutics market is driven by several critical factors, including rising disease awareness, increasing molecular diagnostic adoption, expanded access to biologics, and continued rare cancer research incentives. Improved biopsy practices and access to immunohistochemistry, FISH, and next-generation sequencing (NGS) are enabling earlier and more accurate diagnosis of sarcoma subtypes, allowing oncologists to tailor therapy more effectively. The introduction of companion diagnostics and biomarker-driven treatment protocols is pushing pharmaceutical companies to invest in subtype-specific trials and orphan drug development.

Additionally, the designation of sarcoma drugs as orphan products by regulatory bodies such as the FDA and EMA provides developers with incentives such as tax credits, market exclusivity, and expedited review pathways. These programs have fueled a pipeline of experimental drugs targeting both soft tissue and bone sarcomas. Patient advocacy organizations and global rare cancer alliances are enhancing visibility, fundraising, and research participation, thereby facilitating faster trial recruitment and regulatory approvals. Lastly, healthcare payers are beginning to recognize the cost-benefit balance of targeted therapies in sarcoma management, particularly as real-world data supports improved progression-free survival and quality of life outcomes. These synergistic developments are establishing a solid growth foundation for the global sarcoma therapeutics market.

SCOPE OF STUDY:

The report analyzes the Sarcoma Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Soft Tissue Sarcoma, Osteosarcoma)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Deciphera Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG (Genentech)
  • Fresenius Kabi AG
  • GSK plc
  • Ipsen S.A.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Sanofi S.A.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sarcoma Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Unmet Need in Rare and Heterogeneous Sarcoma Subtypes Propels Therapeutic Innovation
    • Expansion of Precision Oncology Approaches Strengthens Market for Molecularly Targeted Sarcoma Therapies
    • Increased Use of Multimodal Treatment Regimens Drives Demand for Drug Combinations
    • Rising Adoption of Immunotherapy in Advanced Sarcoma Cases Fuels Clinical Trial Activity
    • Development of Selective TKIs and mTOR Inhibitors Expands Treatment Options for Metastatic Disease
    • Growth in Pediatric and Adolescent Sarcoma Cases Spurs Age-Specific Drug Development
    • Orphan Drug Incentives and Regulatory Flexibility Enhance Commercial Viability of Novel Agents
    • Increased Role of Genomic Profiling in Sarcoma Management Expands Scope for Personalized Therapies
    • Collaborations Between Cancer Centers and Biotech Firms Accelerate Pipeline Diversification
    • Use of Companion Diagnostics and Biomarker-Based Stratification Enhances Therapy Response Rates
    • Growing Investment in Cell Therapy and CAR-T Research for Sarcomas Expands Experimental Treatment Pathways
    • Expansion of Clinical Trials in Europe and Asia Improves Global Patient Access to Investigational Drugs
    • Integration of AI in Drug Repurposing Initiatives Accelerates Discovery in Ultra-Rare Sarcoma Subtypes
    • Patient Advocacy and Rare Cancer Networks Propel Policy Support for Accelerated Drug Approval
    • Real-World Evidence and Registry Data Strengthen Reimbursement for Targeted Sarcoma Treatments
    • Shift Toward Maintenance and Recurrence Prevention Therapies Expands Long-Term Treatment Models
    • Adoption of Tumor-Agnostic Therapies Opens New Avenues in Sarcoma With Specific Mutations
    • Increased Demand for Cost-Effective Off-Patent Therapies Spurs Biosimilar Entry in First-Line Settings
    • Cross-Border Research Consortia Support Innovation in Global Sarcoma Therapeutic Pipelines
    • Academic-Industry Co-Development Models Sustain Development in Low-Commercial Viability Subtypes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sarcoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sarcoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Osteosarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Osteosarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • JAPAN
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • CHINA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • EUROPE
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Sarcoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • FRANCE
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • GERMANY
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Sarcoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • INDIA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Sarcoma Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Sarcoma Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Sarcoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030
  • AFRICA
    • Sarcoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Sarcoma Therapeutics by Type - Soft Tissue Sarcoma and Osteosarcoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Sarcoma Therapeutics by Type - Percentage Breakdown of Value Sales for Soft Tissue Sarcoma and Osteosarcoma for the Years 2014, 2025 & 2030

IV. COMPETITION